There are currently 1249 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Daily Doxycycline for Early Syphillis
NCT06683638
Recruiting
The goal of this clinical trial is to learn if doxycycline taken as 200mg daily for 14 days is effective to treat early stage syphilis. This is different from how doxycycline is typically used for syphilis because the full doxycycline dose will be taken at the same time of day, rather than split up into a twice daily regimen. Lab data support that taking the medication as a single daily dose should be effective as treatment, but it has not been studied clinically. The main question this study ai... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Public Health Sexual Health Clinic, Seattle, Washington
Conditions: Syphilis
Register for Updates
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
NCT06246916
Recruiting
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the bra... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Melanoma
Register for Updates
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185
Recruiting
The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Swedish Cancer Institute (SCI), Seattle, Washington
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
NCT04796012
Recruiting
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Gender:
ALL
Ages:
Between 6 months and 30 years
Trial Updated:
06/18/2025
Locations: Seattle Children's, Seattle, Washington
Conditions: Solid Tumor, Rhabdomyosarcoma
Register for Updates
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
NCT06629779
Recruiting
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Harborview Medical Center, Seattle, Washington +2 locations
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People
NCT06821061
Recruiting
The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle, Washington
Conditions: Influenza, COVID-19 (Coronavirus Disease 2019)
Register for Updates
SPEARHEAD-3 Pediatric Study
NCT05642455
Recruiting
This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
06/18/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Osteosarcoma, Neuroblastoma (NBL)
Register for Updates
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
NCT05919511
Recruiting
The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Fred Hutchinson Cancer Research Center, Seattle, Washington
Conditions: cGVHD
Register for Updates
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649
Recruiting
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studies. The master protocol will govern individual study-specific appendices (ISAs) that will represent participants from the individual, completed originator studies. These participants will have the oppor... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309
Recruiting
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastr... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
06/18/2025
Locations: Research Site, Seattle, Washington
Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Register for Updates
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
NCT06876662
Recruiting
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
Register for Updates
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
Gender:
ALL
Ages:
25 years and below
Trial Updated:
06/18/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
Register for Updates